1 The Evaluation of Subcutaneous Proleukin((R)) (interleukin-2) in a Randomized International Trial. Rationale, design, and methods of ESPRIT. Emery S, Abrams DI, Cooper DA, Darbyshire JH, Lane HC, Lundgren JD, and Neaton JD
Control Clin Trials. 2002;23(2):198-220. abstract

2 Regulatory approvals in a large multinational clinical trial. The ESPRIT experience.
McNay LA, Tavel JA, Oseekey K, McDermott CM, Mollerup D, Bebchuk JD, and for the ESPRIT Group.
Control Clin Trials. 2002;23(1):59-66. abstract

3 The feasibility of clinical endpoint trials in HIV infection in the highly active antiretroviral treatment (HAART) era. A Mocroft, J Neaton, J Bebchuk, S Staszewski, F Antunes, B Knysz, M Law, AN Phillips, J Lundgren for the EuroSIDA and ESPRIT study groups.
Clin Trials. 2006 May 206;3(2):119-132 abstract

4 Reporting and evaluation of HIV-related clinical endpoints in two multicenter international clinical trials. A Lifson, FS Rahme, WH Belloso, UB Dragsted, WM El-Sadr, JM Gatell, JF Hoy, EA Krum, R Nelson, C Pedersen, SL Pett, RT Davey for the ESPRIT and SILCAAT Research Groups.
HIV Clin Trials. 2006;7(3):125-141 abstract

More IL-2 related publications: http://www.espritstudy.org/know.asp

Updated: 15 Sep 2006